DataVXACS NanoPaper
journal article·2024-12-10Open access

Targeting Metastasis in Head and Neck Squamous Cell Carcinoma Using Follistatin mRNA Lipid Nanoparticles

Vladislav Grigoriev, Tetiana Korzun, Abraham S. Moses, Antony Jozic, Xinxia Zhu, Jeonghwan Kim, Samuel Newton, Yulia Eygeris, Parham Diba, Ariana L. Sattler, Peter R. Levasseur, Brennan Olson, Ngoc Le, Prem Singh, Kongbrailatpam Shitaljit Sharma, Yoon Tae Goo, Babak Mamnoon, Constanze Raitmayr, Ana Paula Mesquita Souza, Olena R. Taratula, Gaurav Sahay, Daniel L. Marks, Oleh Taratula

ACS Nano· Volume 18· Issue 49
Publisher pageOpen full text
Source abstract

Abstract

Metastatic progression significantly reduces survival rates and complicates treatment strategies in various cancers. Our study introduces an mRNA therapy for metastasis inhibition by targeting activin A overexpression, a pivotal driver of metastasis and cachexia. Utilizing follistatin mRNA lipid nanoparticles, we effectively downregulated activin A both locally in the tumor environment and systemically. This led to a reduction in tumor burden and suppression of metastatic spread in a murine head and neck squamous cell carcinoma model. Treated mice exhibited minimal metastatic occurrence compared to controls. Additionally, our therapy preserved the cross-sectional area of muscle fibers and adipose tissues, combating the muscle and fat wasting typically observed in cancer-associated cachexia. The therapy also demonstrated a favorable safety profile, underscoring its potential for clinical translation. By integrating metastasis-suppressing and cachexia-alleviating mechanisms, our approach represents a promising advancement in comprehensive cancer management. Considering the widespread upregulation of activin A in many cancer types, our therapy holds considerable potential for application across a broad spectrum of oncologic treatments.
Source: openalex_inverted_index · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Nuclear Structure and Function · Cancer, Hypoxia, and Metabolism · Sarcoma Diagnosis and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, 2730 SW Moody Avenue, Portland, Oregon 97201, United States

Department of Biomedical Engineering, Oregon Health and Science University, 3303 SW Bond Avenue, Portland, Oregon 97239, United States

Medical Scientist Training Program, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, United States

Papé Family Pediatric Research Institute, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, United States

College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea

Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health and Science University, 2720 S Moody Ave, Portland, Oregon 97201, United States

Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, United States

Endevica Bio, 1935 Techny Road, Northbrook, Illinois 60062, United States

Funding

National Center for Advancing Translational Sciences · National Cancer Institute · Oregon Health and Science University · Knight Cancer Institute, Oregon Health and Science University

References (76)

Show source-provided references
1. 10.1080/14728222.2020.179935010.1080/14728222.2020.1799350 ↗
2. 10.1002/jcsm.1220910.1002/jcsm.12209 ↗
3. 10.3390/cancers1511300310.3390/cancers15113003 ↗
4. 10.1186/2051-1426-1-S1-P11910.1186/2051-1426-1-S1-P119 ↗
5. 10.1038/npjbcancer.2015.710.1038/npjbcancer.2015.7 ↗
6. 10.1677/JOE-08-054910.1677/JOE-08-0549 ↗
7. 10.1016/j.jid.2017.07.84510.1016/j.jid.2017.07.845 ↗
8. 10.1359/jbmr.09021910.1359/jbmr.090219 ↗
9. 10.1593/neo.8158210.1593/neo.81582 ↗
10. 10.1136/gut.49.3.40910.1136/gut.49.3.409 ↗
11. 10.1016/j.stem.2011.10.00110.1016/j.stem.2011.10.001 ↗
12. 10.1245/s10434-007-9631-110.1245/s10434-007-9631-1 ↗
13. 10.1038/ncomms158510.1038/ncomms1585 ↗
14. 10.1016/j.canlet.2017.01.01110.1016/j.canlet.2017.01.011 ↗
15. 10.1016/j.cell.2010.07.01110.1016/j.cell.2010.07.011 ↗
16. 10.1016/j.cllc.2019.10.01310.1016/j.cllc.2019.10.013 ↗
17. 10.1016/j.physbeh.2010.03.01110.1016/j.physbeh.2010.03.011 ↗
18. 10.1016/j.autneu.2023.10313610.1016/j.autneu.2023.103136 ↗
19. 10.1038/sj.emboj.760100010.1038/sj.emboj.7601000 ↗
20. 10.3390/jpm1106057110.3390/jpm11060571 ↗
21. 10.1021/acsnano.1c0499610.1021/acsnano.1c04996 ↗
22. 10.1002/jcsm.1274510.1002/jcsm.12745 ↗
23. 10.1158/0008-5472.CAN-16-118810.1158/0008-5472.CAN-16-1188 ↗
24. 10.1002/hed.2362710.1002/hed.23627 ↗
25. 10.3892/ol.2015.324810.3892/ol.2015.3248 ↗
26. 10.1038/s41598-019-50865-y10.1038/s41598-019-50865-y ↗
27. 10.3892/ijo.2020.505810.3892/ijo.2020.5058 ↗
28. 10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗
29. 10.1016/j.addr.2022.11441610.1016/j.addr.2022.114416 ↗
30. 10.1089/nat.2018.072110.1089/nat.2018.0721 ↗
31. 10.1016/j.ijpharm.2021.12058610.1016/j.ijpharm.2021.120586 ↗
32. 10.1021/acsnano.4c0508810.1021/acsnano.4c05088 ↗
33. 10.1002/adma.20230337010.1002/adma.202303370 ↗
34. 10.1093/nar/gkq34710.1093/nar/gkq347 ↗
35. 10.1038/s41586-023-06800-310.1038/s41586-023-06800-3 ↗
36. 10.1152/ajpendo.00193.200910.1152/ajpendo.00193.2009 ↗
37. 10.1002/jcsm.1247410.1002/jcsm.12474 ↗
38. 10.1016/j.jbc.2021.10116210.1016/j.jbc.2021.101162 ↗
39. 10.21873/anticanres.1673310.21873/anticanres.16733 ↗
40. 10.1093/nar/gkx24710.1093/nar/gkx247 ↗
41. 10.1016/j.imlet.2023.06.00310.1016/j.imlet.2023.06.003 ↗
42. 10.1158/2767-9764.CRC-23-025810.1158/2767-9764.CRC-23-0258 ↗
43. 10.1038/s41572-020-00224-310.1038/s41572-020-00224-3 ↗
44. 10.1097/PPO.000000000000011510.1097/PPO.0000000000000115 ↗
45. 10.1002/ijc.2881110.1002/ijc.28811 ↗
46. 10.3322/caac.2149210.3322/caac.21492 ↗
47. 10.1002/ijc.3193710.1002/ijc.31937 ↗
48. 10.1016/S0002-9610(05)80109-610.1016/S0002-9610(05)80109-6 ↗
49. 10.3390/cancers701007010.3390/cancers7010070 ↗
50. 10.1038/s41416-019-0601-810.1038/s41416-019-0601-8 ↗
51. 10.1016/j.oraloncology.2012.03.01310.1016/j.oraloncology.2012.03.013 ↗
52. 10.1038/nrdp.2017.10510.1038/nrdp.2017.105 ↗
53. 10.1001/jamaoto.2020.115410.1001/jamaoto.2020.1154 ↗
54. 10.1016/j.nut.2016.11.00810.1016/j.nut.2016.11.008 ↗
55. 10.1093/jnci/89.23.176310.1093/jnci/89.23.1763 ↗
56. 10.1007/s12325-022-02074-910.1007/s12325-022-02074-9 ↗
57. 10.14309/crj.000000000000072410.14309/crj.0000000000000724 ↗
58. 10.1038/s41389-018-0090-210.1038/s41389-018-0090-2 ↗
59. 10.1038/s41565-019-0591-y10.1038/s41565-019-0591-y ↗
60. 10.12688/f1000research.75277.210.12688/f1000research.75277.2 ↗
61. 10.1038/s41598-024-71304-710.1038/s41598-024-71304-7 ↗
62. 10.1093/humrep/deq09710.1093/humrep/deq097 ↗
63. 10.1002/smll.20220443610.1002/smll.202204436 ↗
64. 10.15252/embr.20143924610.15252/embr.201439246 ↗
65. 10.3390/ijms1906170610.3390/ijms19061706 ↗
66. 10.3389/fphar.2019.0044510.3389/fphar.2019.00445 ↗
67. 10.1515/mr-2021-002810.1515/mr-2021-0028 ↗
68. 10.3390/ph1608108810.3390/ph16081088 ↗
69. 10.1096/fj.11-18997710.1096/fj.11-189977 ↗
70. 10.1038/aps.2012.19410.1038/aps.2012.194 ↗
71. 10.1016/j.biocel.2013.04.02310.1016/j.biocel.2013.04.023 ↗
72. 10.1038/cddis.2012.9110.1038/cddis.2012.91 ↗
73. 10.1038/s41467-020-14527-210.1038/s41467-020-14527-2 ↗
74. 10.1038/s41598-017-17204-510.1038/s41598-017-17204-5 ↗
75. 10.1002/jcsm.1299810.1002/jcsm.12998 ↗
76. 10.3758/BF0319314610.3758/BF03193146 ↗